Browse our anti-Glucagon Receptor (GCGR) Antibodies

Human Glucagon Receptor (GCGR) interaction partners

1. 3.0 A-resolution crystal structure of the full-length human glucagon receptor (GCGR) in complex with a glucagon (show GCG Antibodies) analogue and partial agonist, NNC1702

2. work toward the mapping of interactions between the polypeptide hormone glucagon (show GCG Antibodies) and the glucagon receptor

3. 3.0 A crystal structure of full-length GCGR containing both the extracellular domain and transmembrane domain in an inactive conformation

4. This work suggests that RAMP2 (show RAMP2 Antibodies) may modify the agonist activity and trafficking of the GCGR, with potential relevance to production of new peptide analogs with selective agonist activities.

5. Data suggest that GCGR activation proceeds via a mechanism in which transmembrane helix 6 (TM6) is held in an inactive conformation by a conserved polar core and a hydrophobic lock (involving intracellular loop 3, IC3); mutations in the corresponding polar core of GCGR disrupt these inhibitory elements, allow TM6 to swing outward, and induce constitutive G protein signaling.

6. The activation of the GCGR is characterized by the outward movement of the intracellular side of helix VI. In the active state of the GCGR, the Arg173(2.46)-Ser350(6.41) and Glu245(3.50)-Thr351(6.42) hydrogen bonds break, and the chi1 rotamer of Phe322(5.54) changes from perpendicular to parallel to helix VI.

7. In the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R (show GLP1R Antibodies)), the extracellular domain is required for signaling even when the hormone is covalently linked to the transmembrane domain.

8. 2.5 A crystal structure of human GCGR in complex with the antagonist MK-0893, which is found to bind to an allosteric site outside the seven transmembrane helical bundle in a position between TM6 and TM7 extending into the lipid bilayer

9. Molecular dynamics and disulfide crosslinking studies suggest that apo (show C9orf3 Antibodies)-GCGR can adopt both an open and closed conformation associated with extensive contacts between the ECD (show SHFM1 Antibodies) and 7TM domain. Glucagon (show GCG Antibodies) binds to GCGR by a conformational selection mechanism.

10. glucagon (show GCG Antibodies) cell adenomatosis with GCGR germline mutations seems to follow an autosomal-recessive trait.

Mouse (Murine) Glucagon Receptor (GCGR) interaction partners

1. Data, including data from studies using knockout mice, suggest that control of whole-body energy expenditure by Gcgr agonism requires intact Fxr (show NR1H4 Antibodies) signaling and Fgf21 (show FGF21 Antibodies) secretion in liver. (Gcgr = glucagon receptor glucagon (show GCG Antibodies); Fxr (show NR1H4 Antibodies) = farnesoid X receptor (show xpr1 Antibodies); Fgf21 (show FGF21 Antibodies) = fibroblast growth factor-21 (show FGF21 Antibodies))

2. we show that glucagon receptor (GCGR) inhibition with a monoclonal antibody normalized blood glucose and beta-hydroxybutyrate levels. Insulin receptor (show INSR Antibodies) antagonism increased pancreatic beta-cell mass threefold. Normalization of blood glucose levels with GCGR-blocking antibody unexpectedly doubled beta-cell mass relative to that observed with S961 alone and 5.8-fold over control

3. These results show that Slc38a5 (show Slc38a5 Antibodies) is a key component of the feedback circuit between glucagon receptor signaling in the liver and amino-acid-dependent regulation of pancreatic alpha cell mass in mice.

4. GcgR knockout (Gcgr(-/-)) mice displayed lower blood glucose levels accompanied by elevated plasma ghrelin (show GHRL Antibodies) levels. Hyperglycemia was averted in streptozocin treated Gcgr(-/-) mice and the plasma ghrelin (show GHRL Antibodies) level was further increased.

5. glucagon receptor antagonist improves glycemia in diet-induced obese angptl4 (show ANGPTL4 Antibodies) knockout mice without increasing glucagon (show GCG Antibodies) levels or alpha-cell proliferation, underscoring the importance of this protein.

6. Data indicate that the exocrine pancreas in the glucagon receptor Gcgr-/- mice exhibited larger nuclear size than in WT or heterozygous controls, most obviously at old ages.

7. Simultaneous and sufficient activation of GLP1R (show GLP1R Antibodies) is required to reduce GCCR (show NR3C1 Antibodies) mediated blood glucose elevation following administration of a GLP1R (show GLP1R Antibodies)/GCGR co-agonist.

8. Knockdown of liver glucagon receptor in mice reduces blood glucose and increases blood LDL levels.

9. Gcgr(-/-) mice became lethargic (show CACNB4 Antibodies) & cachexic & died early. Autopsy revealed numerous PNETs up to 15 mm in diameter in most well-preserved Gcgr(-/-) pancreata.

10. Data suggest that GcgR activation raises hepatic expression of fibroblast growth factor 21 (FGF21 (show FGF21 Antibodies)) and increases circulating levels of FGF21 (show FGF21 Antibodies); GcgR activation induces body weight loss and stimulates lipid metabolism.